KRAS mutation rate was higher in patients with histologically well/moderate grade tumor (39.4% vs 25.7%, P=.02) or in patients without distant lymph node metastasis (40.8% vs 28.9%, P=.05). The gene discussed is KRAS; the disease is metastatic malignant neoplasm in the lymph nodes.